Development of an oral form of azacytidine: 2'3'5'triacetyl-5-azacytidine.
about
Epigenetic therapies in MDS and AMLEpigenetics and blood disorders.Epigenetic therapy of hematological malignancies: where are we now?Characterization of permeability, stability and anti-HIV-1 activity of decitabine and gemcitabine divalerate prodrugs.Aberrant miRNA promoter methylation and EMT-involving miRNAs in breast cancer metastasis: Diagnosis and therapeutic implications.
P2860
Development of an oral form of azacytidine: 2'3'5'triacetyl-5-azacytidine.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Development of an oral form of azacytidine: 2'3'5'triacetyl-5-azacytidine.
@ast
Development of an oral form of azacytidine: 2'3'5'triacetyl-5-azacytidine.
@en
type
label
Development of an oral form of azacytidine: 2'3'5'triacetyl-5-azacytidine.
@ast
Development of an oral form of azacytidine: 2'3'5'triacetyl-5-azacytidine.
@en
prefLabel
Development of an oral form of azacytidine: 2'3'5'triacetyl-5-azacytidine.
@ast
Development of an oral form of azacytidine: 2'3'5'triacetyl-5-azacytidine.
@en
P2093
P2860
P356
P1476
Development of an oral form of azacytidine: 2'3'5'triacetyl-5-azacytidine.
@en
P2093
Amy Ziemba
Burgess B Freeman
Eugene Hayes
Giuseppe Pizzorno
P2860
P304
P356
10.1155/2011/965826
P577
2011-12-18T00:00:00Z